Leerink Partnrs Has Optimistic Outlook of TWST Q1 Earnings

Twist Bioscience Co. (NASDAQ:TWST) – Leerink Partnrs raised their Q1 2025 earnings estimates for shares of Twist Bioscience in a research note issued on Monday, November 18th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($0.65) per share for the quarter, up from their previous forecast of ($0.71). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.56) per share. Leerink Partnrs also issued estimates for Twist Bioscience’s Q2 2025 earnings at ($0.62) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.34) EPS and FY2026 earnings at ($1.84) EPS.

TWST has been the subject of several other reports. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Barclays dropped their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday. Scotiabank lifted their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday. Robert W. Baird lifted their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Evercore ISI lifted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $51.78.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $41.11 on Thursday. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -11.42 and a beta of 1.78. The company has a 50 day moving average price of $43.93 and a 200-day moving average price of $46.15. Twist Bioscience has a 1-year low of $23.07 and a 1-year high of $60.90.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Signaturefd LLC boosted its position in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new stake in Twist Bioscience in the 2nd quarter valued at about $43,000. Blue Trust Inc. raised its holdings in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after buying an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in Twist Bioscience in the 2nd quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares during the period.

Insiders Place Their Bets

In other news, COO Patrick John Finn sold 6,865 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $296,636.65. Following the transaction, the chief operating officer now owns 161,744 shares of the company’s stock, valued at approximately $6,988,958.24. The trade was a 4.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Emily M. Leproust sold 1,730 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total transaction of $81,206.20. Following the transaction, the chief executive officer now directly owns 495,523 shares in the company, valued at approximately $23,259,849.62. The trade was a 0.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock valued at $4,391,151 in the last 90 days. 3.92% of the stock is owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.